Credit rating agency, ICRA has assigned ‘A1+’ rating to Ranbaxy Laboratories’ Commercial Paper (CP)/Short Term Debt (STD) programme for an enhanced amount of Rs 800 crore. Earlier CP/STD programme of the company for Rs 1,200 crore was also assigned the same rating.
Instruments with these rating are considered to have very strong degree of safety regarding timely payment of financial obligations. Such instruments carry lowest credit risk.
Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
